KBC Securities - MERUS B V (MRUS) Merus Betting Big On Bispecifics: Merus As A Fantastic Opportunity “Near-Us”

Report

KBC Securities

Thomas Vranken

Merus Betting Big On Bispecifics: Merus As A Fantastic Opportunity “Near-Us”

Today we initiate coverage on the Dutch biotech company Merus. Merus offers a compelling investment opportunity, with its innovative antibody platforms, promising lead asset petosemtamab, robust pipeline, and strategic partnerships. The company's strong financial position and ambitious plans for 2025 and beyond position it to make a significant impact on the landscape of cancer treatment. We initiate coverage with a $ 59 TP and Buy rating.

28/04/2025 1 EN

Underlying

MERUS B V

See profile

NL0011606264 NASDAQ Stock Market Netherlands

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

ACF Equity Research

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is integral to patient care, however the mechanism of LCC is little researched and poorly understood. ...

April 29, 2025 April 29, 2025 1 EN

KBC Securities

Morning Notes : AKZA NA, ARGX BB, TWEKA NA, DEME BB, AUTL US, MRUS US

: AKZA NA, ARGX BB, TWEKA NA, DEME BB, AUTL US, MRUS US

April 28, 2025 April 28, 2025 1 EN

Aedifica Solid 1Q25, close to fair value

Aedifica reports 1Q25 results in line with our expectations and consensus forecasts. Negative headlines around the operators slightly overshadow the positive 1Q25 update. However, the news was already communicated to the market 2 weeks ago with a limited impact on the share price performance. YTD the stock has rallied 22.0% and sits at the top of the EPRA index. The rally comes after two years of undervaluation and is driven by a flight to safety amidst tariff concerns. It is now in a 2.1% range from our EUR 70.0 target price. This implies a spot EPRA P/E of 14x. Due to the limited upside, w...

2h / 10m 2h / 10m 1 EN

Guy Sips ... (+6)

Guy Sips
Hilde Van Boxstael
Lynn Hautekeete
Thibault Leneeuw
Thomas Couvreur
Wim Lewi

Morning Notes : ADYEN NA, AED BB, ASM NA, DSFIR NA, MELE BB, ONTEX BB, SMAR BB

: ADYEN NA, AED BB, ASM NA, DSFIR NA, MELE BB, ONTEX BB, SMAR BB

2h / 14m 2h / 14m 1 EN

Thomas Couvreur

Thomas Couvreur

Adyen First Look: Cash App hitting volumes again, limited impact on net result.

Cash App volumes once again causing issues with an 8% decline in Digital volumes, resulting in a 6% gap in overall processed volume expectations. However, given the more limited margin on customers like Cash App and eBay, net result still up 22% YoY, only 1% off from expectations. Solid performance in Unified Commerce and Platform. Management remains confident in their 2025-2026 guidance. We reiterate our Accumulate rating and €1750 TP.

2h / 36m 2h / 36m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Merus Betting Big On Bispecifics: Merus As A Fantastic Opportunity “Near-Us”

We are a financial services provider for several types of professional clients, each with distinct needs.

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Morning Notes : AKZA NA, ARGX BB, TWEKA NA, DEME BB, AUTL US, MRUS US

Aedifica Solid 1Q25, close to fair value

Morning Notes : ADYEN NA, AED BB, ASM NA, DSFIR NA, MELE BB, ONTEX BB, SMAR BB

Adyen First Look: Cash App hitting volumes again, limited impact on net result.

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe